Slideshow: Managing The Peak of Asthma Season
Drug Topics
JULY 25, 2024
The American College of Allergy, Asthma, and Immunology (ACAAI) recently released its 5 tips to help children and their parents stay educated on asthma peak month.
Thu.Jul 25, 2024
201 
STAT+: How UnitedHealth harnesses its physician empire to squeeze profits out of patients
STAT
JULY 25, 2024
UnitedHealth Group started out as a small, Minnesota health insurance company and has since morphed into a modern-day Standard Oil, exerting unmatched dominance over health care in the United States. It’s no secret that UnitedHealth is a colossus: It’s the country’s largest health insurer and the fourth-largest company of any type by revenue, just behind Apple.
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Research Results Show Promise Toward Development of a Universal Influenza Vaccine
Pharmacy Times
JULY 25, 2024
Despite the century-long period of virus evolution, 6 of the 11 primates that received a cytomegalovirus-expressed flu vaccine survived the exposure to H5N1 flu.
Humana inks multi-year partnership with Google to invest deeper in cloud, gen AI technologies
Fierce Healthcare
JULY 25, 2024
Humana inked a new multi-year agreement with Google Cloud to modernize its cloud infrastructure and build out generative AI solutions. | Humana inked a new multi-year agreement with Google Cloud to modernize its cloud infrastructure and build out generative AI solutions.
Position Your Pharmacy for Expansion
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Twice-Yearly Lenacapavir Effective in Significantly Reducing HIV Infections in Cisgender Women
Pharmacy Times
JULY 25, 2024
Adherence and efficacy were both higher in patients with HIV who took twice-yearly lenacapavir compared to those on oral preexposure prophylaxis medication.
Watch: How insurers use doctors to profit off medical codes
STAT
JULY 25, 2024
Insurers like UnitedHealth are profiting off of the Medicare Advantage system, and it’s causing problems for both doctors and patients. Traditional Medicare is run by the federal government, while Medicare Advantage health insurance plans are operated by private companies like UnitedHealth. These privately run plans are still subsidized by government funds.
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
More Trending
Opinion: Adding psychotherapy to drug therapy works, but the FDA may not be able to handle it
STAT
JULY 25, 2024
Many people were stunned when an FDA advisory committee voted “no” on a new drug application for MDMA-assisted psychotherapy for post-traumatic stress disorder (PTSD) earlier this summer. I was not among them. Several things were stacked against approval: The FDA greenlights only about 50 new drugs each year. Drug development is a high-risk business with an overall success rate between 10% and 20%.
Patient Affordability Program for Adalimumab Biosimilar Is Launched at GoodRx
Pharmacy Times
JULY 25, 2024
Patients without insurance may not be able to afford the biosimilar adalimumab-adbm, even if it is available at a more affordable price than its reference product.
Report: CVS to pay $45M as part of settlement with Illinois
Fierce Healthcare
JULY 25, 2024
CVS Health's Caremark has agreed to pay $45 million to Illinois to settle allegations that it failed to pass through rebates in a recent contract, according to a new report. | CVS Health's Caremark has agreed to pay $45 million to Illinois to settle allegations that it failed to pass through rebates in a recent contract, according to a new report.
Dispensing Medication for Muslims: A Guide for Pharmacists
Pharmacy Times
JULY 25, 2024
Despite Muslim patients’ need for halal medication, more than 80% of pharmacists were found to lack knowledge about where to look to find alternative medications that are halal.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Breast cancer study reveals a paradox of mastectomy
STAT
JULY 25, 2024
Breast cancer surgeons have tended not to push patients towards bilateral mastectomy, since data have long shown that the complete removal of both breasts doesn’t improve survival. New data from a large epidemiological study affirmed that, but an accompanying finding is puzzling. Breast cancer survivors who ended up developing a second breast cancer in the opposite or contralateral breast had a higher risk of death, even though preventing that cancer with surgery didn’t change outc
FDA Grants Regenerative Medicine Advanced Therapy Designation for AIC100 to Treat Thyroid Cancer
Pharmacy Times
JULY 25, 2024
AIC100 could meet an unmet medical need to effectively treat individuals with anaplastic thyroid cancer — the most aggressive form of the disease.
STAT+: Federal regulation of health data and AI expected to get a boost after HHS revamp
STAT
JULY 25, 2024
A little-known office within the Department of Health and Human Services is getting a shot in the arm as part of a major agency reorganization announced on Thursday. The Office of the National Coordinator for Health Information Technology, better known as ONC, regulates data standards for health care systems, including the electronic health records that underpin patient care and billing.
Delgocitinib Could Aid Adults With Moderate to Severe Chronic Hand Eczema
Pharmacy Times
JULY 25, 2024
The Lancet published data from DELTA 1 and DELTA 2 trials that displayed treatment success among individuals treated with delgocitinib cream.
5 Reasons to Upgrade Your Pharmacy Management Software
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Universal Health Services beats on revenue, earnings in Q2, raises 2024 forecast
Fierce Healthcare
JULY 25, 2024
Universal Health Services (UHS) raised its full-year revenue and earnings guidance buoyed by strong financial performance in the past six months thanks to acute care growth. | Universal Health Services saw growth in Q2 in profit and revenue offset by lower admissions at its behavioral health facilities.
Pfizer quickly expands its hemophilia B gene therapy's reach with EU approval
Fierce Pharma
JULY 25, 2024
Three months after bagging FDA approval, Pfizer’s hemophilia B gene therapy has been cleared to expand its reach across the pond. | The company's first gene therapy will debut in Europe as Durveqtix. In the U.S., the drug is approved under the brand name Beqvez.
Nemolizumab for Atopic Dermatitis Shows Positive Results in Phase 3 Trials
Drug Topics
JULY 25, 2024
Galderma said the FDA has accepted the company’s Biologics License Application for the therapy based on data from the trials.
Can Pfizer, Sangamo energise haemophilia A gene therapy?
pharmaphorum
JULY 25, 2024
There has been a gene therapy on the market for people with the bleeding disorder haemophilia A since 2022, but take-up has been very slow. Pfizer and Sangamo are hoping for a faster trajectory with their experimental treatment.The partners' one-shot giroctocogene fitelparvovec therapy has cleared a phase 3 trial, showing it was better than regular prophylaxis injections with Factor VIII (FVIII) replacement therapies at reducing bleeding episodes, and could now be heading for regulatory review.
STAT+: A preview of Neurocrine’s muscarinic drug readout
STAT
JULY 25, 2024
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. Welcome back! I’ve been working from home almost this entire summer because of construction on the Red Line. I hate the MBTA. Boston readers know what I mean. This week: “Muscarinics” are hot and Neurocrine Biosciences is the next biotech with a big study readout.
Patient engagement throughout the product lifecycle
pharmaphorum
JULY 25, 2024
Tune in to the Reverba podcast featuring CEO Cheryl Lubbert as she discusses patient engagement throughout the product lifecycle, sharing insights and strategies for success.
STAT+: Roche CEO explains the company’s weight loss drug strategy in crowded market
STAT
JULY 25, 2024
LONDON — In the booming field of weight loss drugs, Roche has been riding high in recent months, with back-to-back positive studies of two experimental medicines that sent the company’s shares up — and those of its rivals down. But on Thursday, company executives faced an onslaught of questions from analysts during an earnings presentation about what came next for the company’s weight loss drugs and how they would stand apart in the wildly competitive field.
Ipsen builds again, licensing Day One glioma drug
pharmaphorum
JULY 25, 2024
Ipsen has signed yet another portfolio-expanding deal – its fifth of the year so far – claiming rights outside the US to a drug for common brain cancer glioma from Day One Biopharmaceuticals.
FDA advisers, frustrated by AZ's Imfinzi design, call for revamp of perioperative lung cancer trials
Fierce Pharma
JULY 25, 2024
The FDA’s Oncologic Drugs Advisory Committee (ODAC) has unanimously called for a revamp of perioperative clinical trial designs in resectable non-small cell lung cancer (NSCLC) to include assessmen | In a discussion prompted by AstraZeneca's application for Imfinzi, the FDA’s Oncologic Drugs Advisory Committee (ODAC) has unanimously called for a revamp of perioperative clinical trial designs in resectable non-small cell lung cancer.
Ascension Illinois to sell most hospitals, several care sites to for-profit Prime Healthcare
Fierce Healthcare
JULY 25, 2024
Ascension Illinois is selling several hospitals and their associated physician practices, post-acute and senior living facilities to Prime Healthcare. | The agreement includes nine hospitals and four additional sites of care, all throughout Illinois. Prime said it would invest $250 million in facility upgrades, capital improvements, technology and system upgrades.
STAT+: Do medical errors creep up at hospitals when interns arrive? Yes, but the ‘July effect’ is minimal.
STAT
JULY 25, 2024
For Dr. Jeremy Faust, July 1 is like New Year’s Day. That’s when thousands of new medical school graduates enter teaching hospitals across the country and provide care to patients as doctors for the first time. “Everything is new and full of possibilities,” said Faust, an emergency physician at Brigham and Women’s Hospital.
Ageing Europe - It’s time we prioritised neurological conditions
pharmaphorum
JULY 25, 2024
Exploring the impact of ageing on Europe and the need to prioritise neurological conditions. Understand the role of neuroscience in addressing these issues.
Opinion: Sponsored genetic testing programs are under fire, further complicating life for people with rare diseases
STAT
JULY 25, 2024
It takes years for most people with a rare disease to learn what is ailing them. Their symptoms may be crystal clear, but the cause isn’t. Efforts by the Department of Justice — an agency not known for its medical expertise — will make things even harder for the millions of Americans , half of them children, with one of these diseases.
Amid Eylea clash, Roche's Vabysmo keeps climbing despite a slowdown in its momentum
Fierce Pharma
JULY 25, 2024
While Roche touted sales and market share increases for eye disease drug Vabysmo on Thursday, there is evidence of a slowdown of its momentum as it battles Regeneron and Bayer’s powerhouse Eylea fr | While Roche touted sales and market share increases for eye disease drug Vabysmo on Thursday, there is evidence of a slowdown of its momentum as it battles Regeneron and Bayer’s powerhouse Eylea.
Six questions about Medicare’s proposed plan to cover digital therapeutics
STAT
JULY 25, 2024
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday. Medicare regulators’ proposal to start paying for some digital therapeutics products created a wave of enthusiasm when it was released earlier this month.
With capacity upgrades ready to roll, Sanofi stands firm on blockbuster sales goal for RSV drug in 2024
Fierce Pharma
JULY 25, 2024
While manufacturing and supply hitches have troubled the rollout of Sanofi’s key respiratory syncytial virus (RSV) drug, the near-term expected approval of a pair of new filling lines is giving the | While manufacturing and supply hitches have troubled the rollout of Sanofi’s key respiratory syncytial virus drug, the near-term expected approval of a pair of new filling lines is giving the French pharma assurance that its AstraZeneca-partnered antibody Beyfortus can breach the billion-dollar thre
Ask the experts: Should pharmacists take on more responsibility or is it a stretch too far?
Outsourcing Pharma
JULY 25, 2024
Back in March this year (2024) under the last UK Conservative government, plans were announced to give greater powers to pharmacy technicians, dental therapists and hygienists after two public consultations.
Extensive pharmacological review on Bauhinia racemosa Lam medicinal plant whose leaves are used to make Indian cigarettes (beedi’s)
Pharma Tutor
JULY 25, 2024
Extensive pharmacological review on Bauhinia racemosa Lam medicinal plant whose leaves are used to make Indian cigarettes (beedi’s) admin Fri, 07/26/2024 - 10:52 Devansh Mehta* M.Pharmacy in Pharmacology, M.B.A. in Pharmaceutical Marketing and Hospital Administration, Founding Medical Writing Director, TRM Writer’s LLP Modipuram, Meerut. *devanshm84@gmail.
With $111M upfront investment, Ipsen secures ex-US rights to Day One's pediatric cancer med
Fierce Pharma
JULY 25, 2024
Just three months after scoring an accelerated FDA approval for Ojemda, Day One Biopharmaceuticals is teaming up with another fellow oncology specialist to grow the medicine's global reach.
STAT+: Pharmalittle: We’re reading about a Viking obesity drug, Bausch Health’s bankruptcy denial, and more
STAT
JULY 25, 2024
Rise and shine, everyone, another busy day is on the way. We can tell because the pace of motor vehicles passing by our window is picking up and the official mascots are busy foraging for varmints passing through the campus grounds. As for us, we are engaged in the usual ritual of brewing cups of stimulation. Our choice today is strawberry cream. As always, you are invited to join us.
Let's personalize your content